Dergiler / European Archives of Medical Research / 2020 / Cilt: 36 - Sayı: 3

Retrospective Evaluation of Patients Diagnosed with Stage I-II Supradiaphragmatic Presentation Hodgkin’s Lymphoma: Treatment Effect and Late-side Effect

Sayfa
166–171
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

But still, giving up smoking and increasing physical activities must be recommended, particularly against lung cancer and ischemic heart disease.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The long-term treatment outcomes of patients with Hodgkin’s lymphoma are important, as such patients have increased lifespans.
📊
Temel Bulgular & Veri:Treatment options must be evaluated particularly for secondary malignancy risk and heart health.Methods: We retrospective re-evaluated a total of 113 patients (all) who had received radiotherapy and/or chemotherapy for stage I-II disease out of 320 patients with Hodgkin’s lymphoma who presented to and were treated at the Okmeydanı Training and Research Hospital Radiation Oncology Clinic between January 1974 and December 1997, and who then continued regular follow-up.
💡
Sonuç & Katkı:But still, giving up smoking and increasing physical activities must be recommended, particularly against lung cancer and ischemic heart disease.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: The long-term treatment outcomes of patients with Hodgkin’s lymphoma are important, as such patients have increased lifespans. Treatment options must be evaluated particularly for secondary malignancy risk and heart health.Methods: We retrospective re-evaluated a total of 113 patients (all) who had received radiotherapy and/or chemotherapy for stage I-II disease out of 320 patients with Hodgkin’s lymphoma who presented to and were treated at the Okmeydanı Training and Research Hospital Radiation Oncology Clinic between January 1974 and December 1997, and who then continued regular follow-up. I this period,only anterior mantle and anterior-posterior mantle treatment and/or chemoterapy, were evaluated for long-term side effects and efficacy.Results: We compared 42 patients who had received only anterior radiotherapy (group 1) and 71 patients who had received anteroposterior radiotherapy (group 2). Recurrence was detected in 15 patients in group 1 and in 20 patients in group 2. Six patients in group 1 and 16 patients in group 2 died. The 5-year survival rate for group 1 and group 2 was 77.18% and 71.33%, respectively, and the respective 10-year survival rates were 70.8% and 67.16%. The secondary malignancies detected were lung cancer (3 patients), hemangiosarcoma (1 patient), larynx carcinoma (1 patient), neurofibromatosis (1 patient), and thyroid carcinoma (1 patient).Conclusion: We discuss the patients’ quality of life in addition to the possible late adverse effects of the treatments given the increased curability and survival in Hodgkin’s lymphoma. The aim is to minimize the treatment-related adverse effects, given patients’ longer life expectancy. For this reason, it is currently being tried to improve the quality of life and survival by reducing the risk of organs and heart doses in terms of secondary cancer such as lung and breast, ischemic heart disease by different methods such as anteror field radiotherapy. But still, giving up smoking and increasing physical activities must be recommended, particularly against lung cancer and ischemic heart disease.

🔖

Bu Makaleye Atıf Yap

BERBER, T. (2022). Retrospective Evaluation of Patients Diagnosed with Stage I-II Supradiaphragmatic Presentation Hodgkin’s Lymphoma: Treatment Effect and Late-side Effect. European Archives of Medical Research, Cilt: 36 - Sayı: 3, 166–171. https://ajindex.com/articles/650407

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Schaapveld M, Aleman BMP, van Eggermond AM, Janus CPM, Krol ADG, van der Maazen et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma. N Engl J Med 2015;373:2499-511. van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CPM, Krol ADG, Hauptmann M, et al. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J Clin Oncol 2016;34:235-43.
  2. Milgrom SA, Chi PCM, Pinnix CC, Aristophanous M, Umfleet W, Hancock D, et al. Rainbows and Butterflies: Individualized IMRT Planning for Mediastinal Lymphoma. IJROBP 2017;99:61. Ashby D. Practical statistics for medical research. Douglas G. Altman, Chapman and Hall, London, 1991. No. of pages: 611.Statistics in medicine 1991;10:1635-6.
  3. Perez CA, Brady LW, Editors Hodgkins Disease and Richard T. Hoppe; 1997.
  4. Akkaya AÖİ, Özgün D. Hodgkin Hastalığında histopatolojik tipler ve epidemiyoloji. GATA Bülteni 1979;21:487-93. Cancer DeVita. Principles and Practice of Oncology. Philadelphia, Lipincott. 1997;1819-58.
  5. Foon KAFR, Lymhomas Beutler E, Lictman MA, Coller BS, Kipps TJ (eds) Williams Hematology fifth Edition Mc Grav Hill, inc. 1995:1076-96. Rosenthal DS. Eyre HJ. Hodgkin’s disease and Non Hodgkin’s lymphomas in Murphy GP LW, Rayman El editors. American Cancer Society Textbook of Clinical Oncology 2nd Edition Atlanta: American Cancer Society; 1995.
  6. Belkaid MI, Briegre J, Djebbara Z, Beldjord K, Andrieu JM, Colonna P. Comparison of Epstein-Barr Virus Markers in Reed-Sternberg Cells in Adult Hodgkin’s Disease Tissues from an Industrialized and a Developing Country. Leuk Lymphoma 1995;17:163-8.
  7. Zarate-Osorno A, Roman LN, Kingma DW, Meneses-Garcia A, Jaffe ES. Hodgkin’s disease in Mexico. Prevalence of Epstein-Barr virus sequences and correlations with histologic subtype. Cancer 1995;75:1360-6.
  8. Jarrett AF, Armstrong AA, Alexander E. Epidemiology of EBV and Hodgkin’s lymphoma. Ann Oncol 1996;4(Suppl 7):5-10. Kaplan HS. On the natural history, treatment, and prognosis of Hodgkin’s disease. Harvey Lect 1968;64:215-59.
  9. Swerdlow AJ, Douglas AJ, Hudson GV, Hudson BV, Bennett MH, MacLennan KA. Risk of second primary cancers after Hodgkin’s disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 1992;304:1137-43.
  10. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 1993;85:25-31. van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den BeltDusebout AW, Boice Jr JD